GMAB Nov 2024 20.000 put
| Previous close | 2.3800 |
| Open | 2.3800 |
| Bid | 0.0000 |
| Ask | 5.0000 |
| Strike | 20.00 |
| Expiry date | 2024-11-15 |
| Day's range | 2.3800 - 2.3800 |
| Contract range | N/A |
| Volume | |
| Open interest | 32 |
Business WireGenmab to Present New and Updated Results From Multiple Clinical Trials Evaluating Epcoritamab Across Various B-Cell Malignancies at the 2024 European Hematology Association (EHA) Congress
COPENHAGEN, Denmark, May 14, 2024--Genmab A/S (Nasdaq: GMAB) announced today that multiple abstracts evaluating epcoritamab, a T-cell engaging bispecific antibody administered subcutaneously, will be presented at the 2024 European Hematology Association (EHA) Congress, being held in Madrid, Spain and virtually, June 13-16, 2024.
GlobeNewswireTransactions in Connection with Share Buy-back Program
Company Announcement COPENHAGEN, Denmark; May 13, 2024 – Genmab A/S (Nasdaq: GMAB). On March 15, 2024, Genmab announced the initiation of a share buy-back program to repurchase up to DKK 3.5 billion worth of shares.The share buy-back program is expected to be completed no later than December 16, 2024. The following transactions were executed under the program from May 6, 2024 to May 10, 2024: Trading PlatformNo. of sharesAverage price (DKK)Total value (DKK)Accumulated through last announcement 6
- GlobeNewswire
Capital Increase in Genmab as a Result of Employee Warrant Exercise
Company Announcement COPENHAGEN, Denmark; May 7, 2024 – Genmab A/S (Nasdaq: GMAB) will increase its share capital by 6,959 shares as a consequence of the exercise of employee warrants. The increase is effected without any preemption rights for the existing shareholders of the company or others. The shares are subscribed in cash at the following price per share of nominally DKK 1: 2,171 shares at DKK 1,025.00,2,790 shares at DKK 1,032.00,98 shares at DKK 1,161.00,729 shares at DKK 1,334.50,343 sh
